Бельгія - англійська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - virus polio type ii, strain p712, 2ab >= 100000 ccid50/0,1 ml - oral suspension - poliomyelitis virus - poliomyelitis oral, monovalent, live attenuated

Бельгія - англійська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - virus polio type i, strain lsc, 2ab >= 1000000 ccid50/0,1 ml; virus polio type iii, strain leon 12a, 1b >= 600000 ccid50/0,1 ml - oral suspension - poliomyelitis virus - poliomyelitis oral, bivalent, live attenuated

Кенія - англійська - Pharmacy and Poisons Board

glaxosmithkline pharmaceutical kenya limited p.o. box 78392 - 00507, nairobi, kenya - virus polio type 1, strain lsc, 2ab; virus polio… - oral suspension - virus polio type 1, strain lsc, 2ab… - poliomyelitis oral bivalent live attenuated

Кенія - англійська - Pharmacy and Poisons Board

china sinopharm international corporation… 4, huixindongjie, chaoyang district, beijing - virus strain polio virus seed (sabin strain) type… - oral drops - each dose of 2 drops (0.1ml) contains polio virus… - poliomyelitis oral bivalent live attenuated

Канада - англійська - Health Canada

sanofi pasteur limited - filamentous haemagglutinin; pertussis toxoid; pertactin; tetanus toxoid; fimbriae types 2 and 3 (fim); poliovirus type 1 mahoney (inactivated); poliovirus type 2 mef1 (inactivated); poliovirus type 3 saukett (inactivated); diphtheria toxoid - suspension - 5mcg; 2.5mcg; 3mcg; 5lf; 5mcg; 29unit; 7unit; 26unit; 2lf - filamentous haemagglutinin 5mcg; pertussis toxoid 2.5mcg; pertactin 3mcg; tetanus toxoid 5lf; fimbriae types 2 and 3 (fim) 5mcg; poliovirus type 1 mahoney (inactivated) 29unit; poliovirus type 2 mef1 (inactivated) 7unit; poliovirus type 3 saukett (inactivated) 26unit; diphtheria toxoid 2lf - vaccines

Канада - англійська - Health Canada

sanofi pasteur limited - pertussis toxoid; filamentous haemagglutinin; fimbriae; pertactin; diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett - suspension - 20mcg; 20mcg; 5mcg; 3mcg; 15lf; 5lf; 40unit; 8unit; 32unit - pertussis toxoid 20mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg; pertactin 3mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit - vaccines

Канада - англійська - Health Canada

sanofi pasteur limited - pertussis toxoid; filamentous haemagglutinin; fimbriae; pertactin; diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett; haemophilus influenzae type b-prp; tetanus protein - liquid - 20mcg; 20mcg; 5mcg; 3mcg; 15lf; 5lf; 40unit; 8unit; 32unit; 10mcg; 30mcg - pertussis toxoid 20mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg; pertactin 3mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit; haemophilus influenzae type b-prp 10mcg; tetanus protein 30mcg - vaccines

Канада - англійська - Health Canada

sanofi pasteur limited - pertactin; pertussis toxoid; diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett; haemophilus influenzae type b-prp; tetanus protein; filamentous haemagglutinin; fimbriae - suspension - 3mcg; 20mcg; 15lf; 5lf; 29unit; 7unit; 26unit; 10mcg; 30mcg; 20mcg; 5mcg - pertactin 3mcg; pertussis toxoid 20mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney 29unit; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1 7unit; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett 26unit; haemophilus influenzae type b-prp 10mcg; tetanus protein 30mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg - vaccines

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)); polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)); polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) - suspension for injection - active: polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)) polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)) polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) excipient: formaldehyde phenoxyethanol polysorbate 80 water for injection - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommendations for the use of live and inactivated poliovirus vaccines are described in the national immunisation guidelines. 1. general recommendations. it is recommended that all infants, unimmunised children and adolescents not previously immunised be vaccinated routinely against paralytic poliomyelitis. ipol should be offered to patients who have refused opv, or in whom opv is contraindicated. 2. ipol is also indicated for: · the primary vaccination of immunocompromised individuals of all ages (see precautions), and household contacts of such individuals (when vaccination is indicated) · unvaccinated or inadequately vaccinated (*) adults, particularly if at increased risk of exposure to live poliovirus, including: · travellers to areas or countries where poliomyelitis is epidemic or endemic; · laboratory workers handling specimens which may contain polioviruses; · health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who had not completed a primary series of vaccination or not received a booster dose since infancy.

Європейський Союз - англійська - EMA (European Medicines Agency)

sanofi pasteur msd, snc - purified diphtheria toxoid, purified tetanus toxoid, purified pertussis toxoid, purified pertussis filamentous haemagglutinin, hepatitis b surface antigen, inactivated type 1 poliovirus (mahoney), inactivated type 2 poliovirus (mef 1), inactivated type 3 poliovirus (saukett), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - this combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis b caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by haemophilus influenzae type b.